In a move that could reshape the medical‑device landscape, Apollo Global Management is reportedly in advanced discussions to acquire Johnson & Johnson’s orthopedics business, DePuy Synthes. Bloomberg News, citing unnamed sources, said the transaction could be valued at close to $20 billion and might be finalized within weeks.
Why the deal matters
DePuy Synthes is a leading producer of hip, knee and shoulder implants, as well as a broad range of surgical instruments. The unit generated $9.3 billion in sales in 2025, underscoring its importance to the overall healthcare market. By separating the orthopedics segment, Johnson & Johnson aims to focus on higher‑growth areas such as pharmaceuticals and medical‑technology innovations.
Potential impact on the industry
If Apollo completes the purchase, the private‑equity firm would add a major, cash‑generating healthcare platform to its portfolio. Apollo has a track record of investing in and growing medical‑device companies, and the acquisition could provide additional capital for research, product development, and expansion into new markets.
Industry analysts note that a deal of this size reflects continued confidence in the demand for orthopedic solutions, driven by an aging population and rising rates of joint‑replacement surgeries. The infusion of private‑equity resources could accelerate innovation and improve supply‑chain efficiency, potentially benefiting hospitals and patients alike.
Johnson & Johnson’s strategic plan
Johnson & Johnson announced last year that it intends to spin off DePuy Synthes into a standalone company within the next 18 to 24 months. The move is part of a broader strategy to sharpen the company’s focus on higher‑growth healthcare segments, including pharmaceuticals, biologics, and advanced medical‑technology platforms.
Separating the orthopedics unit allows Johnson & Johnson to streamline its operations and allocate capital more effectively. The company has not commented publicly on the Apollo talks, and a spokesperson declined to provide further details.
What comes next
Both Apollo Global Management and Johnson & Johnson have not responded to requests for comment from Reuters. The deal, if it proceeds, would still require regulatory approval and the usual due‑diligence processes. Stakeholders will be watching closely to see how the transaction aligns with broader trends in healthcare consolidation.
For now, the potential acquisition signals a continued appetite among private‑equity firms for large‑scale investments in medical‑device businesses, a sector that remains resilient amid broader economic fluctuations.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
